Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma

The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to preven...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogene
Autors principals: Rodriguez-Blanco, J, Pednekar, L, Penas, C, Li, B, Martin, V, Long, J, Lee, E, Weiss, WA, Rodriguez, C, Mehrdad, N, Nguyen, DM, Ayad, NG, Rai, P, Capobianco, AJ, Robbins, DJ
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5680121/
https://ncbi.nlm.nih.gov/pubmed/28714964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.232
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars